Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 4, 2025

Calenduloside E from B. animalis B960 enhances glibenclamide efficacy and alleviates drug-induced side effects via the IRS1/PI3K/AKT pathway in T2D

View Full Paper
Ask AI
Bookmark
Share

Authors

JZJiachao ZhangSSSiyuan ShenLLLiting Lu

Discussion

Loading...

Member takes

Overview

Probiotic Bifidobacterium animalis improves glibenclamide efficacy and reduces side effects via IRS1/PI3K/AKT signaling.

Key Points

  • Combined Bifidobacterium animalis B960 and glibenclamide therapy significantly reduced blood glucose levels in type 2 diabetes.
  • The coadministration improved insulin sensitivity and increased beneficial metabolite levels in vivo.
  • B960 mitigated glibenclamide-induced side effects like hepatotoxicity and inflammation effectively.
  • The study presents a promising strategy for enhancing diabetes treatment while minimizing drug toxicity.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/689a0f8de6551bb0af8d0ea6https://doi.org/10.21203/rs.3.rs-7088573/v1
View Full Paper
Ask AI
Bookmark
Share